Burhan Turgut

Prof. Dr. Burhan Turgut


Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2021 in Internal and Emergency Medicine
Verified
Journal Article
Closed access
PDF file
SBSemih Başcı
Semih Başcı
NANaim Ata
Naim Ata
FAFevzi Altuntaş
Fevzi Altuntaş
TYTuğçe Nur Yiğenoğlu
Tuğçe Nur Yiğenoğlu
MDMehmet Sinan Dal
Mehmet Sinan Dal
ŞBŞuayip Birinci
Şuayip Birinci

1 June 2011 in Journal of the Neurological Sciences
Verified
Journal Article
Closed access
BTBurhan Turgut
Burhan Turgut
NTNilda Turgut
Nilda Turgut
YÇYahya Çelik
Yahya Çelik
ETEmre Tekgündüz
Emre Tekgündüz
GPGülsüm Emel Pamuk
Gülsüm Emel Pamuk
MDMuzaffer Demir
Muzaffer Demir

1 September 2002 in Annals of Hematology
Verified
Journal Article
Closed access
PDF file
BTBurhan Turgut
Burhan Turgut
VÖVural Ö.
Vural Ö.
DMDemir M.
Demir M.
KMKaldir M.
Kaldir M.

1 February 2021 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
FAFevzi Altuntas
Fevzi Altuntas
TYTugce Nur Yigenoglu
Tugce Nur Yigenoglu
SBSemih Başcı
Semih Başcı
MDMehmet Sinan Dal
Mehmet Sinan Dal
SKSerdal Korkmaz
Serdal Korkmaz
MEMehmet Ali Erkurt
Mehmet Ali Erkurt

12 January 2024 in Pathogens
Verified
Journal Article
Open access
PDF file
AYAlpay Yeşilaltay
Alpay Yeşilaltay
DMDilek Muz
Dilek Muz
BEBerna ERDAL
Berna ERDAL
TBTürker Bilgen
Türker Bilgen
BBBahadır Batar
Bahadır Batar
BABurcu Altındağ Avcı
Burcu Altındağ Avcı
This study aimed to explore the effectiveness and safety of Myxoma virus (MYXV) in MM cell lines and primary myeloma cells obtained from patients with multiple myeloma. Myeloma cells were isolated from MM patients and cultured. MYXV, lenalidomide, and bortezomib were used in MM cells. The cytotoxicity assay was investigated using WST-1. Apoptosis was assessed through flow cytometry with Annexin V/PI staining and caspase-9 concentrations using ELISA. To explore MYXV entry into MM cells, monoclonal antibodies were used. Moreover, to explore the mechanisms of MYXV entry into MM cells, we examined the level of GFP-labeled MYXV within the cells after blocking with monoclonal antibodies targeting BCMA, CD20, CD28, CD33, CD38, CD56, CD86, CD117, CD138, CD200, and CD307 in MM cells. The study demonstrated the effects of treating Myxoma virus with lenalidomide and bortezomib. The treatment resulted in reduced cell viability and increased caspase-9 expression. Only low-dose CD86 blockade showed a significant difference in MYXV entry into MM cells. The virus caused an increase in the rate of apoptosis in the cells, regardless of whether it was administered alone or in combination with drugs. The groups with the presence of the virus showed higher rates of early apoptosis. The Virus, Virus + Bortezomib, and Virus + Lenalidomide groups had significantly higher rates of early apoptosis (p < 0.001). However, the measurements of late apoptosis and necrosis showed variability. The addition of MYXV resulted in a statistically significant increase in early apoptosis in both newly diagnosed and refractory MM patients. Our results highlight that patient-based therapy should also be considered for the effective management of MM.

1 December 2021 in Transfusion and Apheresis Science
Verified
Journal Article
Closed access
TYTuğçe Nur Yiğenoğlu
Tuğçe Nur Yiğenoğlu
SBSemih Başcı
Semih Başcı
DŞDerya Şahin
Derya Şahin
Turgay UlasTurgay Ulas
Turgay Ulas
MDMehmet Sinan Dal
Mehmet Sinan Dal
FAFevzi Altuntaş
Fevzi Altuntaş